Appendix 3B

New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12, 04/03/13

Name of entity	
Novogen Limited ("Novogen")	
ABN	
37 063 259 754	
313-37 131	

We (the entity) give ASX the following information.

Part 1 - All issues

You must complete the relevant sections (attach sheets if there is not enough space).

+Class of +securities issued or to be issued Fully paid ordinary share (Share)

- Number of *securities issued or to be issued (if known) or maximum number which may be issued
- A. 381,817
- B. 5,243,467
- C. 1,500,000

TOTAL = 7,125,284 Shares

Principal of the 3 terms +securities if options, (e.g. exercise price and expiry date; if partly paid +securities, amount outstanding and due dates for payment; if +convertible securities, the conversion price and dates for conversion)

Fully-paid ordinary voting shares Ranks pari passu with all existing Ordinary Shares

⁺ See chapter 19 for defined terms.

Do the *securities rank equally All the shares referred to in item 2 will rank 4 in all respects from the +issue pari passu with all existing Ordinary Shares date with an existing +class of quoted +securities? If the additional *securities do not rank equally, please state: the date from which they do the extent to which they participate for the next dividend, (in the case of a trust, distribution) interest payment the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment \$0.125 5 Issue price or consideration B. \$0.15 C. \$0.15 Purpose of the issue The Shares referred to in the item 2 were issued (If issued as consideration for pursuant to the receipt of various notifications to the acquisition of assets, clearly exercise options. identify those assets) Is the entity an +eligible entity 6a that has obtained security holder approval under rule 7.1A? If Yes, complete sections 6b - 6h in relation to the +securities the subject of this Appendix 3B, and comply with section 6i 6b The date the security holder 12 November 2014 resolution under rule 7.1A was passed 6c Number of *securities issued N/A without security holder approval under rule 7.1

6d	Number of *securities issued with security holder approval under rule 7.1A	N/A	
6e	Number of *securities issued	7,125,284 Shares	
	with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)		
6f	Number of *securities issued under an exception in rule 7.2	N/A	
6g	If *securities issued under rule	N/A	
95	7.1A, was issue price at least 75%	14/71	
	of 15 day VWAP as calculated		
	under rule 7.1A.3? Include the tissue date and both values.		
	Include the source of the VWAP		
	calculation.		
6h	If *securities were issued under	N/A	
	rule 7.1A for non-cash		
	consideration, state date on which valuation of		
	consideration was released to		
	ASX Market Announcements		
6i	Calculate the entity's remaining	Listing Rule 7.1: 4,217,044	
	issue capacity under rule 7.1 and		
	rule 7.1A – complete Annexure 1 and release to ASX Market	Listing Rule 7.1A: 2,822,46	4
	Announcements	Total = 7,039,508	
-	+Issue dates	A 11 May 2015	
7	Note: The issue date may be prescribed by	A. 11 May 2015 B. 11 May 2015	
	ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a	C. 13 May 2015	
	pro rata entitlement issue must comply with the applicable timetable in Appendix 7A.		
	Cross reference: item 33 of Appendix 3B.		
0		Number	+Class
8	Number and +class of all +securities quoted on ASX	361,952,526	Ordinary Shares
	(including the +securities in		
	section 2 if applicable)		

⁺ See chapter 19 for defined terms.

9 Number and *class of all *securities not quoted on ASX (including the *securities in section 2 if applicable)

Number	⁺ Class
5,800,634	Unlisted options with exercise price of \$0.125 and expiry date of 18/11/2015.
1,466,470	Unlisted options with exercise price of \$0.15 and expiry date of 16/12/2019.
2,199,521	Unlisted options with exercise price of \$0.15 and expiry date of 18/12/2019.
60,000,000	Unlisted convertible notes, with face values of \$1,500,000

Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)

N/A			

Part 2 - Pro rata issue

11	Is security holder approval required?	
12	Is the issue renounceable or non-renounceable?	
13	Ratio in which the *securities will be offered	
14	*Class of *securities to which the offer relates	
15	⁺ Record date to determine entitlements	
16	Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?	
17	Policy for deciding entitlements in relation to fractions	

18	Names of countries in which the entity has security holders who will not be sent new offer documents	
	Note: Security holders must be told how their entitlements are to be dealt with. Cross reference: rule 7.7.	
	Closs reference. Tule 7.7.	
19	Closing date for receipt of acceptances or renunciations	

⁺ See chapter 19 for defined terms.

20	Names of any underwriters	
21	Amount of any underwriting fee or commission	
22	Names of any brokers to the issue	
23	Fee or commission payable to the broker to the issue	
24	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of security holders	
25	If the issue is contingent on security holders' approval, the date of the meeting	
26	Date entitlement and acceptance form and offer documents will be sent to persons entitled	
27	If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders	
28	Date rights trading will begin (if applicable)	
29	Date rights trading will end (if applicable)	
20	How do cognitive holders call	
30	How do security holders sell their entitlements <i>in full</i> through a broker?	
31	How do security holders sell <i>part</i>	
,	of their entitlements through a broker and accept for the balance?	

Appendix 3B Page 6 04/03/2013

⁺ See chapter 19 for defined terms.

32	of the	do security holders dispose eir entitlements (except by nrough a broker)?	
33	⁺ Issue	e date	
	•	uotation of securitie	S oplying for quotation of securities
34	Type (tick o	of *securities one)	
(a)	X	+Securities described in Part	1
(b)			nd of the escrowed period, partly paid securities that become fully paid, en restriction ends, securities issued on expiry or conversion of convertible
Entiti	es tha	t have ticked box 34(a)	
Addi	tional	securities forming a nev	v class of securities
Tick to docum		e you are providing the informat	ion or
35			securities, the names of the 20 largest holders of the he number and percentage of additional *securities
36			r securities, a distribution schedule of the additional umber of holders in the categories
37		A copy of any trust deed for	the additional ⁺ securities

⁺ See chapter 19 for defined terms.

Entities that have ticked box 34(b) 38 Number of *securities for which ⁺quotation is sought *Class of *securities for which 39 quotation is sought Do the *securities rank equally in 40 all respects from the +issue date with an existing +class of quoted *securities? If the additional +securities do not rank equally, please state: the date from which they do the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment Reason for request for quotation 41 now Example: In the case of restricted securities, end of restriction period (if issued upon conversion of another *security, clearly identify that other *security)

⁴² Number and *class of all *securities quoted on ASX (including the *securities in clause 38)

Number	+Class

Appendix 3B Page 8 04/03/2013

⁺ See chapter 19 for defined terms.

Quotation agreement

- [†]Quotation of our additional [†]securities is in ASX's absolute discretion. ASX may quote the [†]securities on any conditions it decides.
- 2 We warrant the following to ASX.
 - The issue of the +securities to be quoted complies with the law and is not for an illegal purpose.
 - There is no reason why those *securities should not be granted *quotation.
 - An offer of the *securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any *securities to be quoted and that no-one has any right to return any *securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the *securities be quoted.
- If we are a trust, we warrant that no person has the right to return the ⁺securities to be quoted under section 1019B of the Corporations Act at the time that we request that the ⁺securities be quoted.
- We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before †quotation of the †securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here:Date:13/05/2015......

(Director/Company secretary)

Print name:Lionel Mateo......

== == == ==

⁺ See chapter 19 for defined terms.